Race Oncology (ASX:RAC) - Cotización, noticias y análisis

Resumen de acción RAC

Race Oncology Limited, empresa biotecnológica mundial en fase clínica, se centra en el tratamiento del cáncer.

RAC fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Análisis de riesgos

Los beneficios han disminuido un 26.5% al año en los últimos 5 años

Tiene menos de 1 año de cash runway

No tiene ingresos significativos (A$6M)

Los accionistas han sido diluidos en el último año

Competidores de Race Oncology Limited

PYC Therapeutics

ASX:PYC

AU$411.4m

Aroa Biosurgery

ASX:ARX

AU$175.5m

Dimerix

ASX:DXB

AU$175.9m

Orthocell

ASX:OCC

AU$78.5m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Race Oncology
Historical stock prices
Current Share Price	AU$1.31
52 Week High	AU$1.93
52 Week Low	AU$0.64
Beta	1.5
1 Month Change	-5.42%
3 Month Change	75.84%
1 Year Change	-29.38%
3 Year Change	-57.33%
5 Year Change	2,083.33%
Change since IPO	394.34%

Noticias y actualizaciones recientes

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Jan 23

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05

Recent updates

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Jan 23

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01

Rentabilidad de los accionistas

	RAC	AU Biotechs	Mercado AU
7D	-4.4%	1.9%	0.03%
1Y	-29.4%	-8.1%	4.2%

Rentabilidad vs. Industria: RAC obtuvo unos resultados inferiores a los del sector Australian Biotechs , que el año pasado arrojó un rendimiento del -10.2%.

Rentabilidad vs. Mercado: RAC obtuvo unos resultados inferiores a los del mercado Australian, que fue del 3.9% el año pasado.

Volatilidad de los precios

Is RAC's price volatile compared to industry and market?
RAC volatility
RAC Average Weekly Movement	11.9%
Biotechs Industry Average Movement	11.7%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.7%
10% least volatile stocks in AU Market	3.5%

Precio estable de las acciones: El precio de las acciones de RAC ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de RAC (12%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2011	n/a	Daniel Tillett	www.raceoncology.com

Race Oncology Limited, empresa biotecnológica mundial en fase clínica, se centra en el tratamiento del cáncer. Su principal producto, el bisantreno, es una pequeña molécula antracénica quimioterapéutica. La empresa está desarrollando el bisantreno para atender las necesidades no cubiertas de los pacientes en múltiples indicaciones oncológicas, explorando la lucha contra el cáncer y la cardioprotección.

Resumen de fundamentos de Race Oncology Limited

¿Cómo se comparan los beneficios e ingresos de Race Oncology con su capitalización de mercado?
Estadísticas fundamentales de RAC
Capitalización bursátil	AU$217.29m
Beneficios(TTM)	-AU$11.17m
Ingresos (TTM)	AU$5.82m

37.4x

Ratio precio-ventas (PS)

-19.4x

Ratio precio-beneficio (PE)

¿Está RAC sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de RAC
Ingresos	AU$5.82m
Coste de los ingresos	AU$2.87m
Beneficio bruto	AU$2.95m
Otros gastos	AU$14.13m
Beneficios	-AU$11.17m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.067
Margen bruto	50.73%
Margen de beneficio neto	-192.14%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado RAC a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción RAC

Recompensas

Análisis de riesgos

Competidores de Race Oncology Limited

ASX:PYC

AU$411.4m

ASX:ARX

AU$175.5m

ASX:DXB

AU$175.9m

ASX:OCC

AU$78.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New minor risk - Shareholder dilution

New major risk - Financial position

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer

Race Oncology Limited, Annual General Meeting, Nov 27, 2023

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Recent updates

New minor risk - Shareholder dilution

New major risk - Financial position

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer

Race Oncology Limited, Annual General Meeting, Nov 27, 2023

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

New minor risk - Share price stability

New minor risk - Financial data availability

Race Oncology Limited Announces Board Changes

New minor risk - Market cap size

Race Oncology Limited Announces Board Changes

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Race Oncology Limited Appoints Damian Clarke-Bruce as Director

Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial

Race Oncology Limited, Annual General Meeting, Feb 21, 2023

Board Member recently bought AU$50k worth of stock

Board Member recently bought AU$99k worth of stock

Race Oncology Limited Appoints Damian Clarke-Bruce as Managing Director, Effective 1 February 2023

Race Oncology Limited Announces It Has Submitted A Human Ethics Application to Hunter New England Human Research Ethics Committee Seeking Approval to Commence the Observational Stage of A Planned Phase 1/2B Clinical Trial of Zantrene

Race Oncology Limited Appoints Daniel (Danny) Sharp as an Independent Non-Executive Director

Race Oncology Limited Receives Positive Guidance on Zantrene Via Pre-IND Meeting with US FDA

High number of new and inexperienced directors

Race Oncology Ltd Announces Management Changes

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited, Annual General Meeting, Nov 24, 2022

Race Oncology Limited Develops Improved Iv Formulation of Zantrene

Race Oncology Limited Initiates New Drug Discovery Program

Board Member recently bought AU$165k worth of stock

Race Oncology Limited Shares Further Interim Results from Preclinical Cardioprotection Program in Collaboration with Researchers from the University of Newcastle

Race Oncology Limited Announces Interim Results from its Preclinical Melanoma Research Program

Race Oncology Limited Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe

Race Oncology Limited Announces the Dose Escalation Phase 1b Stage of the Relapsed or Refractory Acute Myeloid Leukaemia (R/R AML) Trial Running At the Chaim Sheba Medical Centre, Israel

Race Oncology Limited Appoints Guy Breitenbucher to Its Scientific Advisory Board

Race Oncology Limited Receives Governance Approval for AML EMD & MDS Trial

High number of new and inexperienced directors

Race Oncology Limited Receives Human Ethics Approval for Its Open Label Clinical Trial of Zantrene in Patients with Extramedullary Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited Announces Preclinical & Clinical Programs Update

Board Member recently bought AU$56k worth of stock

Race Oncology Limited Announces MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene

Race Oncology Limited Appoints Christina Manfre as Chief Financial Officer

Non-Independent Non-Executive Chairman recently sold AU$995k worth of stock

Board Member recently bought AU$59k worth of stock

Insider recently sold AU$4.4m worth of stock

Race Oncology Limited Announces Interim Results from the Zantrene® Preclinical Heart Safety Research Program Led by Eminent Cardiotoxicity Researchers, Associate Professors Aaron Sverdlov and Doan Ngo

Non-Independent Non-Executive Chairman exercised options to buy AU$9.8m worth of stock.

Non-Independent Non-Executive Chairman recently bought AU$710k worth of stock

Non-Executive Chairman recently sold AU$193k worth of stock

Non-Executive Chairman exercised options to buy AU$5.7m worth of stock.

Insider recently sold AU$4.3m worth of stock

Race Oncology Limited Executes Contract to Commence Phase 1b/2 AML Trial at Chaim Sheba Israel

Insider recently sold AU$4.8m worth of stock

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Insider recently sold AU$6.6m worth of stock

Race Oncology Limited Announces Compelling Preclinical Breast Cancer Results

Insider recently sold AU$2.1m worth of stock

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?